Characterization of proteoglycans associated with mouse splenic AA amyloidosis.
We here report for the first time on the chemical characteristics of proteoglycans associated with mouse splenic reactive AA amyloid. Amyloid was induced in CBA/J mice by two different procedures; conventional casein treatment and by employing Freund's complete adjuvant, accelerated by Trypan Blue. Pulse-labelling was employed at distinct stages during amyloid development, followed by [35S]proteoglycan characterization of organ extracts. Repetitive 35S injections were also administered during the phase where amyloid deposition occurred most rapidly. Proteoglycans were extracted with guanidine in the presence of protease inhibitors and purified. The results showed that the production of proteoglycans is dramatically enhanced during amyloidogenesis, the glycosaminoglycan and proteoglycan accumulation being not only dependent on alterations in proteoglycan catabolism, but rather on increased synthesis. The increment could be demonstrated even at the stage before microscopic detection of amyloid deposits, clearly suggesting that the upregulation of proteoglycan expression precedes amyloid fibril formation. Two major proteoglycans were found to accumulate in advanced splenic amyloid; one a heparan sulphate proteoglycan of approx. 200 kDa with a core protein of 70 kDa, the other a chondroitin sulphate proteoglycan of smaller size. Moreover, free dermatan sulphate chains seemed to specifically accumulate in the organs during amyloid fibrillogenesis. We suggest that free glycosaminoglycans may be a specific feature of amyloidosis and that different proteoglycans and glycosaminoglycans play a role in formation and stabilization of amyloid fibrils in vivo.
Department of Rheumatology, University of Tromsø, Norway.
T
T
Stenstad
J H
JH
Magnus
G
G
Husby
D000686:Amyloidosis / Q000378:metabolism*; D000818:Animals; D015153:Blotting, Western; D002364:Caseins / Q000633:toxicity; D002850:Chromatography, Gel; D002852:Chromatography, Ion Exchange; D004357:Drug Synergism; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D005620:Freund's Adjuvant / Q000633:toxicity; D006025:Glycosaminoglycans / Q000378:metabolism; D007150:Immunohistochemistry; D051379:Mice; D008808:Mice, Inbred CBA; D008854:Microscopy, Electron; D008970:Molecular Weight; D011509:Proteoglycans / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism*; D000685:Serum Amyloid A Protein / Q000187:drug effects / Q000378:metabolism*; D013154:Spleen / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D013158:Splenic Diseases / Q000378:metabolism*; D016707:Tissue Fixation; D014343:Trypan Blue / Q000633:toxicity
D002364:Caseins; D006025:Glycosaminoglycans; D011509:Proteoglycans; D000685:Serum Amyloid A Protein; D005620:Freund's Adjuvant; D014343:Trypan Blue